Jan 29, 2025, 07:52
Kelsey Pan: Encorafenib, cetuximab and nivolumab in patients with BRAF V600E mutated mCRC
Kelsey Pan, Heme/Onc Chief Fellow at MD Anderson Cancer Center, shared a post on X:
“Grateful for the opportunity to work with the incredible Van Morris on this phase I/II trial of encorafenib, cetuximab and nivolumab in patients with BRAF V600E mutated mCRC who progressed on prior treatment with BRAF + EGFR targeted treatment.
While the addition of Nivo did not seem to overcome resistance after progression on prior E+C, there remains a role of E+C+N in the BRAF tx naive population.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 27, 2025, 11:53
Feb 27, 2025, 11:45
Feb 27, 2025, 11:44
Feb 27, 2025, 11:35
Feb 27, 2025, 11:23
Feb 27, 2025, 11:22
Feb 27, 2025, 11:17
Feb 27, 2025, 11:09
Feb 27, 2025, 10:49